| P50 | author | Adele L. Boskey | Q42152178 |
| P2093 | author name string | Erin Carter | |
| | Nancy Pleshko | |
| | Kostas Verdelis | |
| | Renee Bargman | |
| | Cathleen Raggio | |
| | Edward DiCarlo | |
| | Ram Posham | |
| P2860 | cites work | RANK is essential for osteoclast and lymph node development | Q24598872 |
| | Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand | Q24653311 |
| | The receptor activator of nuclear factor-kappaB ligand inhibitor osteoprotegerin is a bone-protective agent in a rat model of chronic renal insufficiency and hyperparathyroidism. | Q33229834 |
| | The RANKL inhibitor OPG-Fc increases cortical and trabecular bone mass in young gonad-intact cynomolgus monkeys | Q33279942 |
| | Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer | Q34813227 |
| | Defective pro alpha 2(I) collagen synthesis in a recessive mutation in mice: a model of human osteogenesis imperfecta | Q36125438 |
| | Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis | Q36368706 |
| | Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. | Q36860987 |
| | RANKL inhibition through osteoprotegerin blocks bone loss in experimental periodontitis. | Q36973041 |
| | Towards a better understanding and new therapeutics of osteopetrosis | Q37074250 |
| | Osteogenesis Imperfecta: update on presentation and management | Q37135434 |
| | The effects of RANKL inhibition on fracture healing and bone strength in a mouse model of osteogenesis imperfecta | Q37167038 |
| | Comparable outcomes in fracture reduction and bone properties with RANKL inhibition and alendronate treatment in a mouse model of osteogenesis imperfecta. | Q37579579 |
| | Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis | Q40038407 |
| | Restoration of disturbed tooth eruption in osteopetrotic (op/op) mice by injection of macrophage colony-stimulating factor | Q42438223 |
| | CSF-1, RANKL and OPG regulate osteoclastogenesis during murine tooth eruption | Q42483441 |
| | A controlled study of the effects of alendronate in a growing mouse model of osteogenesis imperfecta | Q43782018 |
| | Bisphosphonate-induced osteopetrosis | Q44532555 |
| | RANKL is a marker and mediator of local and systemic bone loss in two rat models of inflammatory arthritis | Q44936799 |
| | Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate | Q45100395 |
| | RANKL inhibition with osteoprotegerin increases bone strength by improving cortical and trabecular bone architecture in ovariectomized rats | Q46212098 |
| | Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial | Q46393065 |
| | Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. | Q46459616 |
| | Bisphosphonate-induced osteopetrosis: novel bone modeling defects, metaphyseal osteopenia, and osteosclerosis fractures after drug exposure ceases | Q46573745 |
| | Effects of catecholamines on blood pressure in the long bone marrow cavity in rats with bisphosphonate-induced osteopetrosis. | Q46755412 |
| | Pamidronate in children and adolescents with osteogenesis imperfecta: effect of treatment discontinuation | Q46909938 |
| | RANKL inhibition: a novel strategy to decrease femoral head deformity after ischemic osteonecrosis | Q48412778 |
| | Fluorescence-based staining for tartrate-resistant acidic phosphatase (TRAP) in osteoclasts combined with other fluorescent dyes and protocols. | Q51035051 |
| | Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2. | Q52192178 |
| | Reduction of osteoclasts in a critical embryonic period is essential for inhibition of mouse tooth eruption. | Q53945603 |
| | Delayed triple helix formation of mutant collagen from patients with osteogenesis imperfecta. | Q54214029 |
| | Osteopetrosis, a New Recessive Skeletal Mutation on Chromosome 12 of the Mouse | Q67444875 |
| | Inhibition by diphosphonates of bone resorption in mice and comparison with grey-lethal osteopetrosis | Q69511050 |
| | The effects of pamidronate on mechanical properties, growth and structural changes in rat bones | Q71875070 |
| | Bisphosphonate modulates proliferation and differentiation of rat periodontal ligament cells during wound healing | Q73148148 |
| | Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction | Q75288496 |
| | Osteoclastogenesis inhibitory factor exhibits hypocalcemic effects in normal mice and in hypercalcemic nude mice carrying tumors associated with humoral hypercalcemia of malignancy | Q77690444 |
| | Lack of the bone remodeling in osteopetrotic (op/op) mice associated with microdontia | Q78028422 |
| | Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment | Q79382770 |
| | Receptor activator of NF-kappa B ligand inhibition suppresses bone resorption and hypercalcemia but does not affect host immune responses to influenza infection | Q80500036 |
| | Effects of bisphosphonates on tooth eruption in children with osteogenesis imperfecta | Q81252402 |
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 495-501 | |
| P577 | publication date | 2012-08-27 | |
| P1433 | published in | Pediatric Research | Q7159215 |
| P1476 | title | High- and low-dose OPG-Fc cause osteopetrosis-like changes in infant mice | |
| P478 | volume | 72 | |